Avid Bioservices Inc (CDMO)

[biopharm]

CP.. what do you think of "cold tumors" popping up with Heat Biologics / BMY?

"March 21 2017

....
.....
To-date, 5 patients have been enrolled in the low tumor infiltrating lymphocytes (TIL) cohort (patients with “cold” tumors). Three of these 5 patients (60%) have experienced significant tumor reduction, which is higher than the 10% response rate of low TIL patients reported for existing data on nivolumab alone.1"
...
...
http://www.heatbio.com/newsroom/press-releases/detail/555/heat-biologics-reports-positive-interim-phase-2-lung-cancer";

------

Now, HS-110 may be a PS Targeting drug....is this possibly why Rahul stopped poppinv up at PPHM cc and also why Jeff Hutchins left and lands over at Heat Biologics... ?

HS-110 (viagenpumatucel-L)

Advanced Non-Small Cell Lung Cancer (“NSCLC”)

HS-110 utilizes ImPACT-modified lung cancer cells to stimulate a patient’s immune system to activate a cytotoxic T cell response against a range of antigens that are known to be expressed by a high proportion of patients with NSCLC. The backbone cell line for HS-110 was selected based on antigenic overlap with patient tumor specimens, including known antigens as well as many additional known and unknown antigens. This approach provides a significant advantage over single antigen approaches by reducing the risk of antigen-loss variants emerging post-treatment and by addressing the underlying genetic and antigenic heterogeneity within tumors.

Heat Biologics is conducting two clinical trials evaluating HS-110 for the treatment of NSCLC:

A multi-arm Phase 2 trial using HS-110 in combination with Bristol-Myers Squibb’s anti-PD-1 checkpoint inhibitor, nivolumab (Opdivo®). For more information reference study protocol NCT02439450 on clinicaltrials.gov.
A Phase 2 randomized, controlled trial using HS-110 in combination with cyclophosphamide. For more information reference study protocol NCT02117024 on clinicaltrials.gov.

http://www.heatbio.com/pipeline/hs-110

-------------------

....and Heat Biologics would require PS Targeting if they use "cyclophosphamide"
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=130082441

....which is why I think HS-110 may be PS Targeting